Liminatus Competitors

Stocks . USA . 
Stock . Liminatus Pharma Class
LIMN Stock   0.59  0.02  3.28%   
Liminatus Pharma Class competes with Alterity Therapeutics, NanoViricides, Generation Bio, Evaxion Biotech, and BioXcel Therapeutics; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Liminatus Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Liminatus Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Liminatus Pharma Correlation with its peers.

Liminatus Pharma vs MAIA Biotechnology Correlation

Excellent diversification

The correlation between Liminatus Pharma Class and MAIA is -0.57 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Liminatus Pharma Class and MAIA in the same portfolio, assuming nothing else is changed.

Moving against Liminatus Stock

  0.81REGN Regeneron Pharmaceuticals Earnings Call TomorrowPairCorr
  0.74VRTX Vertex Pharmaceuticals Earnings Call This WeekPairCorr
  0.71WF Woori Financial GroupPairCorr
  0.63PPERY Bank Mandiri Persero Earnings Call This WeekPairCorr
  0.55NONOF Novo Nordisk AS Earnings Call This WeekPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.030.599.29
Details
Intrinsic
Valuation
LowRealHigh
0.030.579.27
Details
Naive
Forecast
LowNextHigh
0.010.529.22
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.560.710.87
Details

Liminatus Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Liminatus Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Liminatus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Liminatus Pharma Class does not affect the price movement of the other competitor.

High positive correlations

DYAI
+ 0.7
JSPR
DYAI
+ 0.62
NNVC
MAIA
+ 0.6
GBIO
NNVC
+ 0.59
ATHE
EVAX
+ 0.57
NNVC
MAIA
+ 0.57
SABS
  

High negative correlations

SABS
- 0.79
NNVC
MAIA
- 0.71
EVAX
SABS
- 0.63
EVAX
SABS
- 0.53
DYAI
SABS
- 0.5
ATHE
MAIA
- 0.46
JSPR

Risk-Adjusted Indicators

There is a big difference between Liminatus Stock performing well and Liminatus Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Liminatus Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ATHE  3.08 (0.46) 0.00 (0.17) 0.00 
 0.00 
 5.71 
(7.44)
 17.55 
NNVC  4.32 (0.70) 0.00 (1.48) 0.00 
 0.00 
 7.69 
(8.20)
 34.35 
GBIO  1.62  0.00  0.00  0.06  2.03 
(1.95)
 3.39 
(3.99)
 12.30 
MURA  0.48 (0.09) 0.00  1.02  0.00 
 0.00 
 0.96 
(0.95)
 4.77 
EVAX  4.39 (0.65) 0.00  0.78  0.00 
 0.00 
 9.15 
(8.42)
 37.88 
BTAI  4.11 (0.24) 0.00  1.10  0.00 
 0.00 
 8.90 
(7.32)
 22.33 
JSPR  4.31 (0.47) 0.00  5.10  0.00 
 0.00 
 7.73 
(9.04)
 31.75 
DYAI  2.78 (0.30) 0.00 (1.75) 0.00 
 0.00 
 6.82 
(6.32)
 16.34 
SABS  2.85  0.61  0.14 (0.71) 3.12 
(3.56)
 6.13 
(4.05)
 22.52 
MAIA  5.77  1.34  0.19  9.58  6.23 
(6.52)
 12.60 
(8.89)
 35.91 

Liminatus Pharma Competitive Analysis

The better you understand Liminatus Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Liminatus Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Liminatus Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LIMN ATHE NNVC GBIO MURA EVAX BTAI JSPR DYAI SABS
 3.28 
 0.59 
Liminatus
 3.55 
 3.26 
Alterity
 4.76 
 1.00 
NanoViricides
 0.54 
 5.61 
Generation
 0.00 
 2.04 
Mural
 4.23 
 3.40 
Evaxion
 3.57 
 1.62 
BioXcel
 2.52 
 1.55 
Jasper
 3.41 
 0.91 
Dyadic
 0.23 
 4.42 
SAB
Market Volatility
(90 Days Market Risk)
Out of control
Risky
Abnormally volatile
Somewhat reliable
Slightly risky
Very risky
Dangerous
Dangerous
Extremely Dangerous
Unstable
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weak
Weakest
Weakest
Weakest
Weakest
Weakest
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Fair
Risky
Risky
Hazard
Risky
Risky
Small
Risky
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
7.07
34.92
17.93
N/A
6.47
12.25
9.56
4.98
1.72
Net Asset
2.83 M
46.03 M
8.82 M
231.2 M
169.39 M
12.48 M
38.34 M
79.9 M
9.93 M
44.2 M
Profit Margin
N/A
-2.23
N/A
N/A
N/A
-0.71
N/A
N/A
-1.35
163.38
EBITDA
(2.75 M)
(14.63 M)
(8.72 M)
(74.26 M)
(125 M)
(9.79 M)
(44.16 M)
(74.87 M)
(5.38 M)
(28.99 M)
Current Valuation
160.23 M
32.15 M
22.17 M
(25.79 M)
(19.94 M)
29.98 M
111.82 M
(3.3 M)
28.13 M
99.06 M
Operating Margin
N/A
-1.86
N/A
-20.2
N/A
0.4
-143.2
N/A
-1.77
-376.57
Price To Book
N/A
2.17
3.25
0.75
0.64
4.81
3.97
3.97
12.27
1.23
Retained Earnings
(17.52 M)
(225.89 M)
(148.84 M)
(703.04 M)
(159.37 M)
(118.54 M)
(650.2 M)
(240.87 M)
(86.09 M)
(124.17 M)
Current Asset
N/A
14.26 M
24.38 M
N/A
N/A
N/A
609.37 K
N/A
50.41 M
N/A
Beta
0.17
0.02
1.24
2.05
2.97
0.3
0.22
3.07
1.22
0.59
Number Of Employees
5
9
7
115
116
46
37
27
6
63
Shares Outstanding
26.01 M
18.13 M
21.57 M
6.74 M
17.34 M
8.34 M
21.87 M
27.98 M
36.19 M
47.61 M
Cash Flow From Operations
(3.11 M)
(11.45 M)
(8.48 M)
(88.56 M)
(128.54 M)
(12.94 M)
(72.03 M)
(62.6 M)
(3.97 M)
(34.29 M)
Total Debt
5.12 M
155.46 K
1.31 M
93.56 M
8.02 M
10.1 M
102.95 M
1.81 M
5.07 M
4.67 M
Return On Equity
N/A
-0.43
-0.94
-0.81
-1.04
-0.65
-17.67
-1.91
-4.23
0.19
Number Of Shares Shorted
68.1 K
335
657.63 K
2.07 K
417.44 K
105.48 K
1.37 M
3.64 M
147.18 K
1.56 M
Return On Asset
N/A
-0.28
-0.51
-0.27
-0.49
-0.26
-0.67
-0.73
-0.36
-0.23
Book Value Per Share
N/A
0.0035
0.41
7.51
3.19
2.61
-4.45
0.41
-0.018
3.48
Current Liabilities
N/A
1.73 M
6.74 M
N/A
N/A
N/A
1.67 M
N/A
596 K
N/A
Total Asset
2.83 M
46.03 M
8.82 M
231.2 M
169.39 M
12.48 M
38.34 M
79.9 M
9.93 M
44.2 M
Short Ratio
0.11
0.02
2.3
0.03
3.5
1.23
2.36
0.88
0.91
4.84
Debt To Equity
N/A
0.003
0.004
0.27
N/A
0.48
0.38
0.068
7.04
0.16
Target Price
N/A
12.0
6.5
5.25
6.0
14.19
16.75
9.8
5.67
9.38
Shares Owned By Institutions
N/A
1.85
6.64
65.35
46.57
5.85
12.15
73.75
11.39
66.8
Market Capitalization
145.16 M
61.26 M
22.65 M
37.6 M
35.38 M
33.44 M
36.74 M
45.89 M
32.75 M
203.76 M
Price To Earning
N/A
-4.84
-6.02
N/A
N/A
N/A
-2.62
N/A
-18.7
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
-0.01
N/A
N/A
N/A
Price To Sales
N/A
11.26
N/A
2.46
N/A
4.37
48.86
N/A
9.52
1776.47
Net Income
(2.9 M)
(12.15 M)
(9.47 M)
(131.67 M)
(128.51 M)
(10.57 M)
(59.6 M)
(71.27 M)
(5.81 M)
(34.11 M)
Earnings Per Share
-0.16
-0.6
-0.5
-9.37
-6.93
-4.0
-9.29
-5.82
-0.19
-1.56
Shares Owned By Insiders
82.68
N/A
2.78
14.25
13.41
18.38
4.2
1.04
25.17
12.36
Revenue
N/A
5.44 M
N/A
19.89 M
N/A
3.34 M
2.27 M
N/A
3.5 M
1.32 M
Working Capital
(15.79 M)
42.34 M
364.19 K
157.85 M
126.72 M
4.4 M
15.16 M
60.57 M
7.38 M
15.81 M
Cash And Equivalents
N/A
34.81 M
14.07 M
301.17 M
N/A
25.25 M
233.45 M
60.81 M
15.64 M
16.62 M
Cash Per Share
N/A
0.87
1.21
5.07
N/A
1.06
8.33
1.6
0.55
0.39
Gross Profit
N/A
5.31 M
N/A
(32.4 M)
N/A
7.65 M
(212 K)
N/A
2.48 M
(30.33 M)
Day Typical Price
0.6
3.28
1.01
5.6
2.04
3.37
1.64
1.55
0.89
4.42
Accumulation Distribution
9061.78
419.79
17877.98
1261.38
N/A
30348.41
23217.0
23132.08
2766.22
25249.28
Daily Balance Of Power
(0.33)
(1.00)
(1.00)
0.25
0.0
(0.21)
(0.60)
(0.57)
0.4286
0.0435
Period Momentum Indicator
(0.02)
(0.12)
(0.05)
0.03
N/A
(0.15)
(0.06)
(0.04)
0.03
0.01
Rate Of Daily Change
0.97
0.96
0.95
1.01
1.0
0.96
0.96
0.97
1.03
1.0
Day Median Price
0.61
3.29
1.02
5.59
2.04
3.35
1.65
1.55
0.89
4.42
Price Action Indicator
(0.03)
(0.09)
(0.04)
0.035
N/A
(0.03)
(0.06)
(0.01)
0.04
0.01
Relative Strength Index
36.86
45.07
38.55
51.82
42.65
34.73
41.8
42.46
45.42
64.09
Coefficient Of Variation
(844.77)
(1,169)
(880.51)
4141.92
(1,041)
(858.16)
(2,278)
(1,199)
(1,328)
669.34
Mean Deviation
5.48
3.08
4.32
1.62
0.4751
4.39
4.11
4.31
2.78
2.85
Jensen Alpha
(1.03)
(0.46)
(0.70)
0.0034
(0.09)
(0.65)
(0.24)
(0.47)
(0.30)
0.6099
Total Risk Alpha
(1.65)
(0.63)
(1.09)
(0.11)
(0.15)
(1.11)
(0.64)
(0.88)
(0.56)
0.295
Sortino Ratio
N/A
N/A
N/A
(0)
N/A
N/A
N/A
N/A
N/A
0.1374
Downside Variance
N/A
N/A
N/A
4.72
N/A
N/A
N/A
N/A
N/A
14.18
Standard Deviation
8.7
3.98
5.86
2.25
0.8623
5.89
5.46
5.63
3.78
3.87
Kurtosis
9.63
0.249
3.59
1.3
13.13
2.2
1.44
1.17
0.7787
1.57
Potential Upside
7.69
5.71
7.69
3.39
0.9615
9.15
8.9
7.73
6.82
6.13
Treynor Ratio
4.35
(0.17)
(1.48)
0.0556
1.02
0.7821
1.1
5.1
(1.75)
(0.71)
Maximum Drawdown
53.06
17.55
34.35
12.3
4.77
37.88
22.33
31.75
16.34
22.52
Variance
75.69
15.8
34.3
5.04
0.7436
34.71
29.83
31.71
14.28
15.01
Market Risk Adjusted Performance
4.36
(0.16)
(1.47)
0.0656
1.03
0.7921
1.11
5.11
(1.74)
(0.70)
Risk Adjusted Performance
(0.08)
(0.05)
(0.07)
0.0243
(0.07)
(0.08)
(0.02)
(0.05)
(0.05)
0.1166
Skewness
1.19
(0.12)
1.38
0.2292
(3.10)
0.3118
0.4734
(0.62)
0.5201
0.0724
Semi Deviation
N/A
N/A
N/A
2.03
N/A
N/A
N/A
N/A
N/A
3.12
Information Ratio
(0.13)
(0.10)
(0.12)
(0)
(0.17)
(0.13)
(0.06)
(0.09)
(0.09)
0.1336
Value At Risk
(10.98)
(7.44)
(8.20)
(3.99)
(0.95)
(8.42)
(7.32)
(9.04)
(6.32)
(4.05)
Expected Short fall
N/A
N/A
N/A
(1.95)
N/A
N/A
N/A
N/A
N/A
(3.56)
Downside Deviation
N/A
N/A
N/A
2.17
N/A
N/A
N/A
N/A
N/A
3.77
Semi Variance
N/A
N/A
N/A
4.11
N/A
N/A
N/A
N/A
N/A
9.72

Liminatus Pharma Competition Performance Charts

Five steps to successful analysis of Liminatus Pharma Competition

Liminatus Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Liminatus Pharma Class in relation to its competition. Liminatus Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Liminatus Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Liminatus Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Liminatus Pharma Class, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Liminatus Pharma position

In addition to having Liminatus Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Government Funds Thematic Idea Now

Government Funds
Government Funds Theme
Funds or Etfs that invest in fixed income securities issued by national government to finance government spending or to facilitate Federal Reserve monetary policies. The Government Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Government Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Liminatus Pharma Class offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Liminatus Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Liminatus Pharma Class Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Liminatus Pharma Class Stock:
How To Invest In Liminatus
Details
Is Liminatus Stock a good investment?
Details
What is Liminatus Pharma's Net Worth?
Details
Top Sectors
View
Check out Liminatus Pharma Correlation with its peers.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Will Stock sector continue expanding? Could Liminatus diversify its offerings? Factors like these will boost the valuation of Liminatus Pharma. Expected growth trajectory for Liminatus significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Liminatus Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Liminatus Pharma Class's market price often diverges from its book value, the accounting figure shown on Liminatus's balance sheet. Smart investors calculate Liminatus Pharma's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Liminatus Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Understanding that Liminatus Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Liminatus Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Liminatus Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY